Structure-function based development of JC virion specific antagonists for PML
基于结构-功能的 JC 病毒颗粒特异性 PML 拮抗剂的开发
基本信息
- 批准号:8512814
- 负责人:
- 金额:$ 111.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-09-30 至 2014-07-31
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAdenovirusesAffinityAmerican Cancer SocietyArchitectureAreaAttentionBindingBioavailableBiologicalBiologyCaliforniaCancer CenterCancer Center Planning GrantCarbohydratesCell CommunicationCell surfaceCellsChemicalsChemistryCollaborationsCombinatorial SynthesisComplementComplexCore FacilityCyclic PeptidesCyclizationDNA PackagingDNA Tumor VirusesDataDefectDevelopmentDiversity LibraryElementsFacultyG-Protein-Coupled ReceptorsGanglioside GM1GenomicsGoalsHeadHealthHousingHumanImmunologic MonitoringInfectionJC VirusJournalsLaboratoriesLibrariesLigandsManuscriptsMarshalMeasles virusMethodologyMethodsModelingMolecularMolecular StructureMolecular VirologyMolecular WeightMultiple SclerosisMutationNMR SpectroscopyOligosaccharidesPatientsPenetrationPeptidesPharmaceutical PreparationsPolyomaviridaePolyomavirusPolyomavirus InfectionsPositioning AttributePostdoctoral FellowPreventionProgressive Multifocal LeukoencephalopathyPropertyProtein-Carbohydrate InteractionProteinsPublishingQualifyingReceptor CellReovirusResearchResearch PersonnelResolutionRoleSalinumScienceScientistSialic AcidsSideSignal TransductionSimian virus 40SiteSolidSolutionsSpecificityStructural BiologistStructural ChemistryStructureSystemTexasTissuesTrainingTransgenic OrganismsUnited States National Institutes of HealthUniversitiesVirionVirusVirus DiseasesVirus ReceptorsWorkalpha-Defensinsanalogaustinbasecentral nervous system demyelinating disorderchemical synthesiscollegedesignexperiencegraduate studentinhibitor/antagonistmeetingsmouse polyomavirusmutantnovelprofessorprogramsprotein protein interactionreceptorreceptor couplingserotonin receptorsmall molecule librariesstructural biologysuccesstherapy developmentvirology
项目摘要
DESCRIPTION (provided by applicant): This program project brings together an interdisciplinary team of three scientists with unique expertise to functionally target and inhibit human polyomavirus infections. The polyomaviruses in general, and the human polyomaviruses in particular, have been shown to utilize distinct host cell carbohydrates and proteins to infect target cells and tissues. The human polyomavirus JCV is the causative agent of a fatal central nervous system demyelinating disease known as progressive multifocal leukoencephalopathy (PML). The majority of PML cases occur in patients with AIDS but recently PML has also been shown to occur in multiple sclerosis patients being treated with potent immunomodulatory drugs that inhibit immunosurveillance of the CNS. There are currently no drugs in the pipeline that target the virus directly and a major goal of this program is to identify compounds capable of directly inhibiting virus infection. This goal will be accomplished by close collaborative interactions between a team consisting of a polyomavirologist, a structural biologist, and a structural chemist. Project # 1 led by Professor Thilo Stehle will focus on structurally characterizing and identifying sites on the virus that are critical for interacting with host cell surfaces. Project # 2 led by Professor Walter Atwood will introduce site-specific mutations in the virus based on these structures and functionally characterize the mutants for defects in assembly, DNA packaging, cell binding, cell penetration, and infection. Project # 3 led by Professor Dale Mierke will design and synthesize chemical compounds to antagonize virus host cell interactions. These compounds will be functionally screened by Project # 2. The projects will be supported by a chemical synthesis core at Dartmouth College headed by Drs. Mierke and Spaller. An administrative core will be housed at Brown University. The overall goal of this program is to use structural information to derive exquisitely specific inhibitors of polyomavirus infection that are potent, nontoxic, and bioavailable. The three major investigators on the team have built a strong working collaboration that is evidenced by the solid preliminary data supporting this application.
描述(由申请人提供):该计划项目汇集了由三名科学家组成的跨学科团队,他们拥有独特的专业知识,可以在功能上靶向和抑制人类多瘤病毒感染。一般而言,多瘤病毒,特别是人多瘤病毒,已显示利用不同的宿主细胞碳水化合物和蛋白质来感染靶细胞和组织。人类多瘤病毒 JCV 是致命的中枢神经系统脱髓鞘疾病(称为进行性多灶性白质脑病 (PML))的病原体。大多数 PML 病例发生在 AIDS 患者中,但最近也显示 PML 也发生在接受抑制中枢神经系统免疫监视的强效免疫调节药物治疗的多发性硬化症患者中。目前尚无直接针对病毒的药物正在研发中,该计划的主要目标是鉴定能够直接抑制病毒感染的化合物。这一目标将通过由多瘤病毒学家、结构生物学家和结构化学家组成的团队之间的密切合作来实现。由 Thilo Stehle 教授领导的项目#1将重点关注病毒的结构特征和识别位点,这些位点对于与宿主细胞表面相互作用至关重要。由 Walter Atwood 教授领导的项目 #2 将根据这些结构引入病毒中的位点特异性突变,并在功能上表征突变体的组装、DNA 包装、细胞结合、细胞渗透和感染方面的缺陷。由 Dale Mierke 教授领导的项目#3将设计和合成化合物来拮抗病毒宿主细胞的相互作用。这些化合物将由项目 #2 进行功能筛选。这些项目将得到达特茅斯学院化学合成核心的支持,该核心由 Drs.米尔克和斯帕尔。行政核心将设在布朗大学。该项目的总体目标是利用结构信息来衍生出有效、无毒且具有生物利用度的多瘤病毒感染的精确特异性抑制剂。该团队的三位主要研究人员建立了强有力的工作合作,支持该应用的可靠初步数据证明了这一点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Walter J Atwood其他文献
Walter J Atwood的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Walter J Atwood', 18)}}的其他基金
Progressive Multifocal Leukoenephalopathy: Endemic Viruses and Lethal Brain Disease
进行性多灶性白质脑病:地方性病毒和致命性脑病
- 批准号:
10604314 - 财政年份:2020
- 资助金额:
$ 111.79万 - 项目类别:
Progressive Multifocal Leukoenephalopathy: Endemic Viruses and Lethal Brain Disease
进行性多灶性白质脑病:地方性病毒和致命性脑病
- 批准号:
10393583 - 财政年份:2020
- 资助金额:
$ 111.79万 - 项目类别:
相似国自然基金
肝胆肿瘤治疗性溶瘤腺病毒疫苗的研制及其临床前应用性探索
- 批准号:82303776
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
禽腺病毒血清11型反向遗传平台的建立与毒株间致病性差异机制探究
- 批准号:32372997
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
CD46和DSG2双受体在人B组腺病毒感染与致病中的协同作用和机制研究
- 批准号:32370155
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
基于sIgA的V(D)J结构多样性探索腺病毒载体鼻喷新冠奥密克戎疫苗诱导的呼吸道粘膜免疫原性特征
- 批准号:82302607
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
PD-1/PD-L1信号促CD21-B细胞BCR髓外二次编辑降低自身反应性在儿童腺病毒肺炎中的作用机制研究
- 批准号:82370015
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
Collaboratory of AIDS Researchers for Eradication (CARE)
艾滋病根除研究人员合作实验室(CARE)
- 批准号:
9190915 - 财政年份:2016
- 资助金额:
$ 111.79万 - 项目类别:
CC Chemokine Secretion to Protect Antigen-Specific CD4 T Cells from HIV
CC 趋化因子分泌保护抗原特异性 CD4 T 细胞免受 HIV 感染
- 批准号:
7929496 - 财政年份:2009
- 资助金额:
$ 111.79万 - 项目类别:
Structure-function based development of JC virion specific antagonists for PML
基于结构-功能的 JC 病毒颗粒特异性 PML 拮抗剂的开发
- 批准号:
8304292 - 财政年份:2009
- 资助金额:
$ 111.79万 - 项目类别:
CC Chemokine Secretion to Protect Antigen-Specific CD4 T Cells from HIV
CC 趋化因子分泌保护抗原特异性 CD4 T 细胞免受 HIV 感染
- 批准号:
7761148 - 财政年份:2009
- 资助金额:
$ 111.79万 - 项目类别: